Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00464178 · MORE INFO

Limitations, agreements, and source contact

A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma · Source last updated 2022-07-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
true
limitations And Caveats
description
The study was terminated prior to enrollment completion and formal analysis of the primary objectives was never conducted.
point Of Contact
email
DSiegel@hackensackumc.org
organization
Hackensack University Medical Center
phone
551-996-2000
title
Dr. David Siegel
Complete source fields
certain Agreement
pi Sponsor Employee
true
limitations And Caveats
description
The study was terminated prior to enrollment completion and formal analysis of the primary objectives was never conducted.
point Of Contact
email
DSiegel@hackensackumc.org
organization
Hackensack University Medical Center
phone
551-996-2000
title
Dr. David Siegel

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice